International AIDS Vaccine Initiative (IAVI)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From International AIDS Vaccine Initiative (IAVI)
Challenges And Opportunities As mRNA Manufacturing Spreads Its Wings Beyond COVID-19 Vaccines
In the second part of In Vivo's series on mRNA manufacturing, we look at the technology behind the Moderna and Pfizer/BioNTech COVID-19 vaccines. Experts in the field are working on a variety of improvements that will enable quicker, cheaper, surer development and production of what could turn out to be a wide array of vaccines and therapeutics to be churned out by emerging mRNA platforms.
Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
Promising Results In GSK Study Could Break Years Of TB Vaccine Deadlock
GlaxoSmithKline has published results from its latest Phase IIb trial of its investigational tuberculosis vaccine that show a subunit vaccine can reduce pulmonary TB, possibly leading the way for the first new vaccine for TB in over 90 years.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.